

Kerala Co-operative Milk Marketing Federation Ltd.
Milma Bhavan, P.O. Trivandrum-695004
Ph:04712786439,440,441 E-mail: projects@milma.com

TENDER NOTICE
BID REFERENCE :: KCMMF/KHO/PRO/558/2025
NAME OF WORK :E- tender for the Design, Supply, Installation and Commissioning of New Maize Feed Silo Elevator and Conveyor, along with Dismantling of Existing Elevator at Cattle Feed Plant, Malampuzha, Palakkad. Detailed tender notice available in our website www.milma.com.
23.01.2026
Sd/-
MANAGING DIRECTOR.

PPGCL

PRAGRAJ POWER GENERATION COMPANY LTD.

Regd Office: Shatabdi Bhawan, B12 & 13, Sector 4, Gautam Budh Nagar, Noida, Uttar Pradesh-201301
Plant Address: PO-Lohgarh, Tehsil-Bara, Prayagraj(Alehabad), Uttar Pradesh-212107
Phone: +91-120-6102000/6102009 CIN: U40101UP2007PLC032835**NOTICE INVITING EXPRESSION OF INTEREST**

Prayagraj Power Generation Company Limited invites expression of interest (EOI) from eligible vendors for Removal of MS pipe 250 NB & Erection of 250 NB Pipe for Dry Ash Line Buffer Hopper to 6KT Silo of 3x660 MW Thermal Power Plant at Prayagraj Power Generation Company Limited, Bara, Dist. Prayagraj, Uttar Pradesh, India. Details of pre-qualification requirements, bid security, purchasing of tender document etc. may be downloaded using the URL- <https://www.ppgcl.co.in/tenders.php> Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 31st Jan 2026.

**EPACK PREFAB TECHNOLOGIES LIMITED**(previously known as Epack Polymers Private Limited and Epack Prefab Technologies Private Limited)
Registered office: 61-B, Udyog Vihar Surajpur, Kasna Road, Gautam Buddha Nagar, Greater Noida - 201306, Uttar Pradesh, India
CIN: L74999UP1999PLC16066, Website: www.epack.in, Contact no: +91-8130444666.**STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025**

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of the Epack Prefab Technologies Limited ("Company") at its meeting held on January 21, 2026, approved the unaudited financial results (Standalone and Consolidated) of the Company for the quarter and nine months ended on December 31, 2025 and ("Financial Results").

The Financial Results along with the Limited Review Report by M/s. Talati & Talati LLP, Chartered Accountants, (ICAI Firm Registration No.: 110758W/W100377), Statutory Auditors of the Company are available on the website of the Company at www.epack.in, and on the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can also be accessed by scanning the following Quick Response (QR) code



For and behalf of
Epack Prefab Technologies Limited
sd/-
Sanjay Singhania
Managing Director & CEO
DIN: 01291342

Date: 22.01.2026
Place: Noida

**Alivus Life Sciences Limited**

(formerly Glenmark Life Sciences Limited)

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur-413 213, India.
Corporate Office: Technopolis Knowledge Park, A Wing, Office No. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093
Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.alivus.com; Email: complianceofficer@alivus.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025

₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31 Dec'25	30 Sep'25	31 Dec'24	31 Dec'25	31 Dec'24	31 Mar'25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income						
	Revenue from Operations	6,728.89	5,879.80	6,418.44	18,627.15	17,373.39	23,868.84
	Other Income	139.28	147.20	104.56	376.33	244.82	345.70
	Total Income	6,868.17	6,027.00	6,523.00	19,003.48	17,618.21	24,214.54
II	Expenses						
	Cost of Materials Consumed	2,763.62	2,889.61	2,876.16	8,342.98	7,730.48	10,535.02
	Changes in Inventories of Finished Goods and Work-in-Progress	0.56	(400.42)	(23.45)	(385.76)	252.08	273.50
	Employee Benefits Expense	663.70	664.00	656.91	1,943.47	1,849.74	2,516.96
	Finance Costs	14.94	13.18	4.58	40.63	11.54	24.14
	Depreciation and Amortisation Expense	196.58	184.35	151.59	551.57	446.39	606.09
	Other Expenses	988.28	934.91	1,005.74	2,898.92	2,699.57	3,717.52
	Total Expenses	4,627.68	4,285.63	4,671.53	13,391.81	12,989.80	17,673.23
III	Profit Before Exceptional items (I-II)	2,240.49	1,741.37	1,851.47	5,611.67	4,628.41	6,541.31
IV	Exceptional items (Refer Note 4)						
V	Statutory impact of new labour codes	256.57	-	-	256.57	-	-
VI	Profit Before Tax (III-IV)	1,983.92	1,741.37	1,851.47	5,355.10	4,628.41	6,541.31
VII	Tax Expenses						
	Current Tax	539.16	399.51	468.06	1,328.03	1,145.63	1,624.40
	Deferred Tax	(57.85)	41.60	13.81	8.85	45.19	60.64
	Total Tax Expenses	481.31	441.11	481.87	1,336.88	1,190.82	1,685.04
VIII	Profit for the Period / Year (V-VI)	1,502.61	1,300.26	1,369.60	4,018.22	3,437.59	4,856.27
IX	Total Comprehensive Income for the Period / Year (VII+VIII)						
X	Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)	1,502.19	1,303.14	1,365.74	4,017.64	3,426.62	4,843.79
XI	(a) Basic (in ₹)	12.25	10.60	11.18	32.76	28.06	39.63
	(b) Diluted (in ₹)	12.22	10.58	11.14	32.68	27.97	39.52
XII	Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.36	245.36	245.07	245.36	245.07	245.07
	Other Equity excluding Revaluation Reserve	-	-	-	-	-	27,928.65

See accompanying notes to the Financial Results

Notes:

- The financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The above Financial Results were reviewed by the Audit Committee at their meeting held on January 22, 2026, and thereafter approved and taken on record by the Board of Directors at their meeting held on January 22, 2026. The results for the quarter ended December 31, 2025 have been subjected to Limited Review by Walker Chandrik & Co. LLP, the Statutory Auditor of the company, who have expressed an unmodified conclusion on the said results.
- The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).
- Pursuant to the notification issued by the Ministry of Labour and Employment, multiple existing labour legislations have been consolidated into a unified framework comprising four Labour Codes (collectively referred to as the "New Labour Codes"), which became effective from November 21, 2025. The Company has reassessed its employee benefit obligations in accordance with the revised definition of wages. Considering the material, regulatory driven and non recurring nature of this impact, the Company has presented the incremental effect as "Statutory impact of new Labour Codes" under "Exceptional items". The incremental impact, consisting of gratuity amounting to ₹170.02 million and compensated absences amounting to ₹86.55 million, has been recognised in the current reporting period as a past service cost in accordance with the FAQs issued by the Institute of Chartered Accountants of India (ICAI). The Company continues to monitor the finalisation of the Central and State Rules and further clarifications from the Government on other aspects of the Labour Codes, and will provide appropriate accounting effects based on such developments as required.
- As at December 31, 2025, pursuant to Employee Stock Option Plan 2021, 6,00,631 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

The Results along with the Limited Review Report have been uploaded on the Company's website at [https://www.alivus.com/investors/financial-results/](http://www.alivus.com/investors/financial-results/) and can be accessed by scanning the QR code.For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)Yasir Rawjee
Managing Director & CEO

Mumbai, January 22, 2026

**SAGAR CEMENTS LIMITED**

CIN: L26942TG1981PLC002887

Regd. Office : Plot No. 111, Road No.10, Jubilee Hills, Hyderabad-500 033.

Ph.040 23351571, E-mail: info@sagarcements.in, Website: www.sagarcements.in**STATEMENT OF UN-AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025**

(₹ in lakhs)

Sl. No.	Particulars	Consolidated			Standalone		
		For the Quarter ended December 31, 2025 (Un-audited)	For the nine months ended December 31, 2025 (Un-audited)	For the year ended December 31, 2025 (Audited)	For the Quarter ended December 31, 2025 (Un-audited)	For the nine months ended December 31, 2025 (Un-audited)	For the year ended December 31, 2025 (Audited)
		For the Quarter ended December 31, 2024 (Un-audited)	For the nine months ended December 31, 2024 (Un-audited)	For the year ended December 31, 2024 (Audited)	For the Quarter ended December 31, 2024 (Un-audited)	For the nine months ended December 31, 2024 (Un-audited)	For the year ended December 31, 2024 (Audited)
1	Total Income from Operations	59,054	1,86,306	56,388	1,23,839	38,340	1,56,664
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	(7,383)	(9,644)	(6,423)	(25,636)	(2,094)	(11,734)
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	(7,383)	(9,64				